Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Polyclonal antibodies are a heterogeneous mix of antibodies derived from the immune response of multiple B-cells, in which each one recognizes a different epitope on the same antigen. Polyclonal antibodies are composed of a mixture of antibodies that represent the natural immune response to an antigen. Polyclonal antibodies are used in general research applications. Moreover, increasing incidence of cancer across the globe is expected to boost the market growth. According to an article published by Cancer Research UK in 2015, 55,122 new cases of breast cancer were registered in 2015. In the U.K., breast cancer was the most common cancer, accounting for 15% of all new cancer cases in 2015.

The global polyclonal antibody market is estimated to be valued at US$ 943.6 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).

Figure 1. Global Polyclonal Antibody Market Share (%), by Region, 2020

Polyclonal Antibody  | Coherent Market Insights

Rising cases of infectious diseases are expected to propel growth of the global polyclonal antibody market.

Rising incidence of infectious diseases such as Ebola virus worldwide, especially in under-developed countries, is expected to drive the market growth during the forecast period. For instance, according to an article published by the World Health Organization (WHO) in February 2020, the outbreak of Ebola virus in West Africa was the largest outbreak during 2014-2016 and it still continues in various countries. The facts and figures are given below:

Table 1. Ebola virus disease outbreak

Year

Country

Cases

Case Fatality

2018-2020

Democratic Republic of the Congo

3,481

66%

2014-2016

Sierra Leone

14,124

28%

2014-2016

Liberia

10,675

45%

2014-2016

Guinea

3,811

67%

Figure 2. Global Polyclonal Antibody Market Share (%), by Type, 2020

Polyclonal Antibody  | Coherent Market Insights

The ongoing development of polyclonal antibodies in North America is expected to drive the market growth.

North America is expected to hold dominant position in the global polyclonal antibody market owing to ongoing research and development in the region. For instance, in August 2018, SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, announced that its anti-Ebola immunotherapy, SAB-139, offers100% protection against a lethal dose of the Ebola virus in an animal study published in The Journal of Infectious Diseases. The study was conducted by the National Interagency Confederation for Biological Research in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC).

request-sample

Polyclonal Antibody Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 943.6 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.2% 2027 Value Projection: US$ 1,350.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Primary Antibody, Secondary Antibody.
  • By Application: Academic Research, Commercial.
Companies covered:

Abcam plc, GenScript, Merck KGaA., IgY Immune Technologies & Life Sciences Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Genway Biotech, Inc., Geno Technology Inc., DC Biosciences Ltd., Good Biotech Corp, Rockland Immunochemicals, Inc., EpiGentek Group Inc., Innovagen AB., and GeneTex, Inc.

Growth Drivers:
  • Rising incidence of cancer
  • Ongoing development of polyclonal antibodies
  • Adoption of inorganic strategies by key players
Restraints & Challenges:
  • Low purity and concentration levels of specific polyclonal antibodies

Global Polyclonal Antibody Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

Lockdowns in various countries have placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products, and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is expected to limit growth of the global polyclonal antibody market during the forecast period.

Key Players

Major players operating in the global polyclonal antibody market are Abcam plc, GenScript, Merck KGaA., IgY Immune Technologies & Life Sciences Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Genway Biotech, Inc., Geno Technology Inc., DC Biosciences Ltd., Good Biotech Corp, Rockland Immunochemicals, Inc., EpiGentek Group Inc., Innovagen AB., and GeneTex, Inc. among others.

Antibodies are the type of globular proteins produced by the plasma cells. Polyclonal antibodies are produced by different types of plasma B cells and bind to different epitopes in the same antigen. Polyclonal antibodies are heterogeneous mixture of antibodies and are inexpensive to produce. Polyclonal antibodies are used in therapeutics as well as in research applications.

Market Dynamics

Rising incidence of cancer is expected to drive the global polyclonal antibody market growth. For instance, according to an article published by the Cancer Research UK, 367,167 new cases of cancer were reported between 2015 and 2017 in the U.K.

Moreover, ongoing development of polyclonal antibodies is expected to drive the market growth. For instance, in March 2020, GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced that the company is developing a recombinant polyclonal antibody therapy for the treatment of COVID-19.  The recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG) is in development to treat high-risk and severely ill individuals infected with COVID-19.

Key features of the study:

  • This report provides in-depth analysis of the global polyclonal antibody market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global polyclonal antibody market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Abcam plc, GenScript, Merck KGaA., IgY Immune Technologies & Life Sciences Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Genway Biotech, Inc., Geno Technology Inc., DC Biosciences Ltd., Good Biotech Corp, Rockland Immunochemicals, Inc., EpiGentek Group Inc., Innovagen AB. and GeneTex, Inc. among others.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global polyclonal antibody market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global polyclonal antibody market.

Detailed Segmentation:

  • Global Polyclonal Antibody Market, By Type:
    • Primary Antibody
    • Secondary Antibody
  • Global Polyclonal Antibody Market, By Application:
    • Academic Research
    • Commercial
  •  Global Polyclonal Antibody Market, By Region:
    • North America
      • By Type:
        • Primary Antibody
        • Secondary Antibody
      • By Application:
        • Academic Research
        • Commercial
      •  By Country:
        • U.S.
        • Canada
    • Latin America
      • By Type:
        • Primary Antibody
        • Secondary Antibody
      • By Application:
        • Academic Research
        • Commercial
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type:
        • Primary Antibody
        • Secondary Antibody
      • By Application:
        • Academic Research
        • Commercial
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type:
        • Primary Antibody
        • Secondary Antibody
      • By Application:
        • Academic Research
        • Commercial
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type:
        • Primary Antibody
        • Secondary Antibody
      • By Application:
        • Academic Research
        • Commercial
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type:
        • Primary Antibody
        • Secondary Antibody
      • By Application:
        • Academic Research
        • Commercial
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Abcam plc*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • GenScript
    • Merck KGaA.
    • IgY Immune Technologies & Life Sciences Inc.
    • Thermo Fisher Scientific Inc.
    • Takara Bio Inc.
    • Genway Biotech, Inc.
    • Geno Technology Inc.
    • DC Biosciences Ltd.
    • Good Biotech Corp
    • Rockland Immunochemicals, Inc.
    • EpiGentek Group Inc.
    • Innovagen AB
    • GeneTex, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Pest Analysis
    • Regulatory Scenario
    • New Product Launches
    • Collaborations and Agreements
    • Market Trends
  4. Global Polyclonal Antibody Market – Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Market Scenario
    • Impact of COVID-19 Market on the Polyclonal Antibody Products
  5. Global Polyclonal Antibody Market, By Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Primary Antibody
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Secondary Antibody
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Polyclonal Antibody Market, By Application, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Academic Research
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Commercial
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Polyclonal Antibody Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Abcam plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GenScript
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck KGaA.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • IgY Immune Technologies & Life Sciences Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Thermo Fisher Scientific Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Takara Bio Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Genway Biotech, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Geno Technology Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • DC Biosciences Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Good Biotech Corp
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Rockland Immunochemicals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • EpiGentek Group Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Innovagen AB.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GeneTex, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  9. Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 40 market data tables and 35 figures on "Polyclonal Antibody Market” - Global forecast to 2027

FAQgrowicon

Frequently Asked Questions

The global polyclonal antibody market is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).
The global polyclonal antibody market is estimated to be valued at US$ 943.6 million in 2020.
Rising incidence of cancer, development of polyclonal antibodies, and adoption of inorganic strategies by key players are expected to favor the market growth.
The secondary antibody segment is the leading segment based on type in the global polyclonal antibody market during the forecast period (2020-2027).
North America polyclonal antibody market holds the highest revenue share during the forecast period.
Major players operating in the global polyclonal antibody market are Abcam plc, GenScript, Merck KGaA., IgY Immune Technologies & Life Sciences Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Genway Biotech, Inc., Geno Technology Inc., DC Biosciences Ltd., Good Biotech Corp, Rockland Immunochemicals, Inc., EpiGentek Group Inc., Innovagen AB. and GeneTex, Inc. among others.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.